Sanofi - Aventis Groupe: Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting

Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting HARMONIE Phase 3b data reinforce nirsevimab's consistent and high efficacy against infant hospitalizations

Related Keywords

China ,Lisbon ,Lisboa ,Portugal ,Canada ,Philadelphia ,Pennsylvania ,United States ,Japan ,United Kingdom ,Paris ,France General ,France ,Corentine Driancourt ,Pthomas Triomphe ,Nicolas Obrist ,Sandrine Guendoul ,Nathalie Pham ,Sally Bain ,Evan Berland ,Eva Schaefer Jansen ,Simon Drysdale ,Tarik Elgoutni ,Felix Lauscher ,National Medical Products Administration ,European Medicines Agency Ema Priority ,Nasdaq ,Astrazeneca ,Regulatory Agency ,Drug Administration ,Japan Agency For Medical Research ,European Union ,George University Hospital ,China Center ,Euronext ,Burden Of Community ,Vice President ,Infectious Diseases ,University Hospital ,Co Chief Investigator ,Antibody Prevention ,Breakthrough Therapy Designation ,Drug Evaluation ,European Medicines Agency ,Promising Innovative Medicine ,United Kingdom Medicines ,Drug Selection ,Promote New Drug Development ,Japan Agency ,Medical Research ,Business Operating ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Annual Meeting ,European Society ,Paediatric Infectious Diseases ,Young Children ,Global Level ,Systematic Review ,Syncytial Virus Bronchiolitis ,Gefallene Big Techs ,Sanofi ,Eventis ,Roupe ,Dress ,Release ,Nirsevimab ,Elivers ,Reduction ,Infant ,Hospitalizations ,Meal ,World ,Linical ,Trial ,Setting ,